UBRELVY 50 mg/1

UBRELVY 50 mg is a medication containing ubrogepant, used for the acute treatment of migraines. This oral tablet is designed to provide relief from migraine pain and associated symptoms. Ubrogepant is a selective calcitonin gene-related peptide (CGRP) receptor antagonist.

UBRELVY 50 mg is primarily used for the acute treatment of migraines in adults. It is designed to alleviate the pain and other symptoms associated with migraines, such as nausea and sensitivity to light and sound. Ubrogepant works by blocking the activity of CGRP, a protein involved in migraine attacks. This medication is not intended for preventive use but rather for the treatment of active migraine episodes.

Common effects of Ubrevly 50 mg may include nausea, somnolence, and dry mouth. Some users may experience fatigue or dizziness. These effects are generally mild and temporary, but if they persist or worsen, it is advisable to consult a healthcare professional.

UBRELVY 50 mg should be used with caution in individuals with a history of liver disease or severe kidney impairment. It is important to follow the prescribed dosage and not to exceed the recommended amount. This medication should be stored at room temperature and kept out of reach of children.

UBRELVY 50 mg may interact with certain medications, including strong CYP3A4 inhibitors and inducers. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol should be avoided while using this medication, as it may increase the risk of side effects.